Serum Institute of India, the world's largest vaccine maker, is ramping up production of AstraZeneca's Covid-19 shot to have 100 million doses ready by December for an inoculation drive expected to begin across India that same month. SII and the Indian Council of Medical Research (ICMR) are collaborating on the clinical trials of the vaccine in the country. While ICMR has funded the clinical trial site fees, SII is taking care of other expenses for Covishield. At present, SII and ICMR are conducting II/III clinical trial of the vaccine at 15 different centres across the country.
Serum Institute of India, the world's largest vaccine maker, is ramping up production of AstraZeneca's Covid-19 shot to have 100 million doses ready by December for an inoculation drive expected to begin across India that same month. SII and the Indian Council of Medical Research (ICMR) are collaborating on the clinical trials of the vaccine in the country. While ICMR has funded the clinical trial site fees, SII is taking care of other expenses for Covishield. At present, SII and ICMR are conducting II/III clinical trial of the vaccine at 15 different centres across the country. November 14, 2020 at 08:28AM https://ift.tt/3lsKT0x
No comments:
Post a Comment